🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Donor blood stem cells and T cells

Found 299 matching trials

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

PHASE2

The purpose of this study is to find out if removing a specific type of whi...

Status

Terminated

Location

Memorial SloanKettering Cancer Center

Start Date

2018-07-23

Trial ID

NCT03615144

Treatments Being Tested

Melphalan Thiotepa Clofarabine Fludarabine Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)CliniMACS reagents

Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

PHASE1

This is a phase I single center dose escalation study with an extension at ...

Status

Completed

Location

Masonic Cancer Center, University of Minnesota

Start Date

2013-11-08

Trial ID

NCT01634217

Treatments Being Tested

iTreg

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

PHASE2

Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor...

Status

Completed

Location

University of California Davis Cancer Center

Start Date

2007-06

Trial ID

NCT00619645

Treatments Being Tested

busulfan cyclosporine fludarabine phosphate mycophenolate mofetil allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

PHASE2

RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor...

Status

Withdrawn

Location

Children's Memorial Hospital

Start Date

2008-09

Trial ID

NCT00874315

Treatments Being Tested

anti-thymocyte globulin busulfan cyclosporine fludarabine phosphate mycophenolate mofetil tacrolimus allogeneic hematopoietic stem cell transplantation

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

PHASE2

RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total...

Status

Terminated

Location

OHSU Knight Cancer Institute

Start Date

2003-05

Trial ID

NCT00416884

Treatments Being Tested

Campath Fludarabine Total Body Irradiation (TBI)T-Cell Deplete

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

PHASE1

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, s...

Status

Completed

Location

Fred Hutchinson Cancer Research Center

Start Date

1998-12

Trial ID

NCT00107354

Treatments Being Tested

aldesleukin therapeutic allogeneic lymphocytes therapeutic autologous lymphocytes cytarabine etoposide mitoxantrone hydrochloride allogeneic bone marrow transplantation peripheral blood stem cell transplantation

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

PHASE2

This is a genetic disease (transmitted through the parents' genes) called F...

Status

Completed

Location

Children's Hospital Boston

Start Date

2009-09-25

Trial ID

NCT00987480

Treatments Being Tested

Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.CliniMACS device

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE1

This phase I trial studies the side effects and best dose of yttrium Y 90 a...

Status

Completed

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2012-01-09

Trial ID

NCT01503242

Treatments Being Tested

Allogeneic Hematopoietic Stem Cell Transplantation Cyclosporine Fludarabine Phosphate Mycophenolate Mofetil Peripheral Blood Stem Cell Transplantation Total-Body Irradiation Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

PHASE1

The major morbidities of allogeneic hematopoietic stem cell transplant (HSC...

Status

Recruiting

Location

Children's Hospital of Philadelphia

Start Date

2025-03-21

Trial ID

NCT06839456

Treatments Being Tested

Phase 1 Dose Level 1 Phase 1 Dose Level 2 Phase 1 Dose Level 3 Phase 2 Maximum Tolerated Dose determined in Phase 1 Phase 2 Established Dose from prior study, NCT03810196

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

PHASE2

This phase II trial investigates how well a naive T cell depleted graft wor...

Status

Not Yet Recruiting

Location

Seattle Children's Hospital

Start Date

2026-09

Trial ID

NCT07660783

Treatments Being Tested

ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs

Previous Next